If you look on argenx’s website today, you’ll see a burst of confetti. That’s because — in addition to getting a new type of therapy past the FDA for patients with a chronic neuromuscular disease…
The long wait for Novavax’s promising Covid-19 vaccine will soon be over for Europeans.
The European
As the new year rapidly approaches, and gyms and health food stores across America prepare for a wave of people seeking weight loss, Novo Nordisk has announced that it does not expect to meet demand…
CinCor Pharma made some noise earlier this year after raising $143 million in a Series B in October, thanks to a round led by General Atlantic. And now CEO Marc de Garidel, the former chairman and CEO…
Count Novartis in for the burgeoning TIGIT race. After starting the year by plunking down $650 million upfront to license BeiGene’s PD-1 inhibitor — with positive Phase III data stacking up ever since…
The writing was perhaps on the wall for this one back in 2018: Aptose Biosciences has decided to end clinical development of the c-Myc inhibitor APTO-253, a therapy that was the subject of a three…
Senti Biosciences is hopping on the SPAC track with a deal that will provide $296 million in proceeds for the preclinical biotech to move its gene circuit engineered cell and gene therapies toward…
They say good things happen in threes, and BD seems to be hoping that adage rings true for its Cor molecular diagnostic platform.
The FDA greenlighted U.K.-based Sky Medical’s wearable electrical muscle stimulator to help stave off some of the symptoms of chronically blocked vessels such as varicose veins and blood pooling in…
Researchers say they have found a growth hormone in the colon that helps damage DNA, which aides in the aging process. The finding could lead to new therapeutic approaches to aging-associated…
